Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 107


Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma.

Ascierto PA, Ferrucci PF, Fisher R, Del Vecchio M, Atkinson V, Schmidt H, Schachter J, Queirolo P, Long GV, Di Giacomo AM, Svane IM, Lotem M, Bar-Sela G, Couture F, Mookerjee B, Ghori R, Ibrahim N, Moreno BH, Ribas A.

Nat Med. 2019 Jun;25(6):941-946. doi: 10.1038/s41591-019-0448-9. Epub 2019 Jun 6.


Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer, Including Patients Aged 70 Years or Older with Poor Performance Status (CheckMate 153).

Spigel DR, McCleod M, Jotte RM, Einhorn L, Horn L, Waterhouse DM, Creelan B, Babu S, Leighl NB, Chandler JC, Couture F, Keogh G, Goss G, Daniel DB, Garon EB, Schwartzberg LS, Sen R, Korytowsky B, Li A, Aanur N, Hussein MA.

J Thorac Oncol. 2019 May 20. pii: S1556-0864(19)30376-4. doi: 10.1016/j.jtho.2019.05.010. [Epub ahead of print]


The AFMC electives diversification policy: Potential drawbacks and benefits for medical students applying to urology.

Nguyen DD, Lee JY, Couture F, Richard PO, Fahmy N, Perrotte P, Domes T, Bhojani N.

Can Urol Assoc J. 2019 Apr 26. doi: 10.5489/cuaj.6000. [Epub ahead of print] No abstract available.


Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial.

Eng C, Kim TW, Bendell J, Argilés G, Tebbutt NC, Di Bartolomeo M, Falcone A, Fakih M, Kozloff M, Segal NH, Sobrero A, Yan Y, Chang I, Uyei A, Roberts L, Ciardiello F; IMblaze370 Investigators.

Lancet Oncol. 2019 Jun;20(6):849-861. doi: 10.1016/S1470-2045(19)30027-0. Epub 2019 Apr 16. Erratum in: Lancet Oncol. 2019 Jun;20(6):e293.


Perceptions and intentions toward medical assistance in dying among Canadian medical students.

Falconer J, Couture F, Demir KK, Lang M, Shefman Z, Woo M.

BMC Med Ethics. 2019 Apr 2;20(1):22. doi: 10.1186/s12910-019-0356-z.


Predictors of deviation in neurovascular bundle preservation during robotic prostatectomy.

Couture F, Polesello S, Tholomier C, Bondarenko HD, Karakiewicz PI, Nazzani S, Preisser F, El-Hakim A, Zorn KC.

Can J Urol. 2019 Feb;26(1):9644-9653.


Enhanced anti-tumor activity of the Multi-Leu peptide PACE4 inhibitor transformed into an albumin-bound tumor-targeting prodrug.

Kwiatkowska A, Couture F, Ait-Mohand S, Desjardins R, Dory YL, Guérin B, Day R.

Sci Rep. 2019 Feb 14;9(1):2118. doi: 10.1038/s41598-018-37568-6.


FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.

Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul JL, Choné L, Francois E, Artru P, Biagi JJ, Lecomte T, Assenat E, Faroux R, Ychou M, Volet J, Sauvanet A, Breysacher G, Di Fiore F, Cripps C, Kavan P, Texereau P, Bouhier-Leporrier K, Khemissa-Akouz F, Legoux JL, Juzyna B, Gourgou S, O'Callaghan CJ, Jouffroy-Zeller C, Rat P, Malka D, Castan F, Bachet JB; Canadian Cancer Trials Group and the Unicancer-GI–PRODIGE Group.

N Engl J Med. 2018 Dec 20;379(25):2395-2406. doi: 10.1056/NEJMoa1809775.


Improving the Selectivity of PACE4 Inhibitors through Modifications of the P1 Residue.

Dianati V, Navals P, Couture F, Desjardins R, Dame A, Kwiatkowska A, Day R, Dory YL.

J Med Chem. 2018 Dec 27;61(24):11250-11260. doi: 10.1021/acs.jmedchem.8b01381. Epub 2018 Dec 13.


Evaluation of PACE4 isoforms as biomarkers in thyroid cancer.

Fradet L, Temmar R, Couture F, Belzile M, Fortier PH, Day R.

J Otolaryngol Head Neck Surg. 2018 Oct 19;47(1):63. doi: 10.1186/s40463-018-0311-x.


Increasing C-Terminal Hydrophobicity Improves the Cell Permeability and Antiproliferative Activity of PACE4 Inhibitors against Prostate Cancer Cell Lines.

Dianati V, Kwiatkowska A, Couture F, Desjardins R, Dory YL, Day R.

J Med Chem. 2018 Sep 27;61(18):8457-8467. doi: 10.1021/acs.jmedchem.8b01144. Epub 2018 Sep 17.


Isolated peritoneal carcinomatosis from metastatic castration-resistant prostate cancer and associated biliary obstruction: A case report.

Couture F, Chin J, Chong J, Tanguay S.

Urol Case Rep. 2018 Aug 12;21:10-11. doi: 10.1016/j.eucr.2018.08.007. eCollection 2018 Nov. No abstract available.


Use of the AccuVein AV400 during RARP: an infrared augmented reality device to help reduce abdominal wall hematoma.

Law KW, Ajib K, Couture F, Tholomier C, Bondarenko HD, Preisser F, Karakiewicz PI, Zorn KC.

Can J Urol. 2018 Aug;25(4):9384-9388.


Real-world patient- and caregiver-reported outcomes in advanced breast cancer.

Lambert-Obry V, Gouault-Laliberté A, Castonguay A, Zanotti G, Tran T, Mates M, Lemieux J, Chabot P, Prady C, Couture F, Lachaine J.

Curr Oncol. 2018 Aug;25(4):e282-e290. doi: 10.3747/co.25.3765. Epub 2018 Aug 14.


Association of STAT-3 rs1053004 and VDR rs11574077 With FOLFIRI-Related Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients.

De Mattia E, Cecchin E, Montico M, Labriet A, Guillemette C, Dreussi E, Roncato R, Bignucolo A, Buonadonna A, D'Andrea M, Coppola L, Lonardi S, Lévesque E, Jonker D, Couture F, Toffoli G.

Front Pharmacol. 2018 Apr 13;9:367. doi: 10.3389/fphar.2018.00367. eCollection 2018.


Prostate cancer biochemical recurrence after salvage radiotherapy: first look into risk stratification and prognosis.

Couture F, Tholomier C, Zorn KC.

BJU Int. 2018 Mar;121(3):320-321. doi: 10.1111/bju.13978. No abstract available.


NUP98-BPTF gene fusion identified in primary refractory acute megakaryoblastic leukemia of infancy.

Roussy M, Bilodeau M, Jouan L, Tibout P, Laramée L, Lemyre E, Léveillé F, Tihy F, Cardin S, Sauvageau C, Couture F, Louis I, Choblet A, Patey N, Gendron P, Duval M, Teira P, Hébert J, Wilhelm BT, Choi JK, Gruber TA, Bittencourt H, Cellot S.

Genes Chromosomes Cancer. 2018 Jun;57(6):311-319. doi: 10.1002/gcc.22532. Epub 2018 Mar 28.


Assessment of urology postgraduate trainees' competencies in flexible ureteroscopic stone extraction.

Aloosh M, Couture F, Fahmy N, Elhilali MM, Andonian S.

Can Urol Assoc J. 2018 Feb;12(2):52-58. doi: 10.5489/cuaj.4570. Epub 2017 Dec 1.


WITHDRAWN: PACE4 Proteolytically Processes LOXL2 with little impact on its catalytic activity.

Okada K, Moon HJ, Finney J, Couture F, Day R, Mure M.

J Biol Chem. 2017 Nov 28. pii: jbc.C117.810978. doi: 10.1074/jbc.C117.810978. [Epub ahead of print]


Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.

Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Gokmen E, Bashford A, Ruiz Borrego M, Kim SB, Jakobsen EH, Ciceniene A, Inoue K, Overkamp F, Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Moran S, Yao B, Xu F, Auerbach A, Buyse M, Chan A; ExteNET Study Group.

Lancet Oncol. 2017 Dec;18(12):1688-1700. doi: 10.1016/S1470-2045(17)30717-9. Epub 2017 Nov 13.


Supplemental Content

Loading ...
Support Center